Combination of Se-methylselenocysteine, D-α-tocopheryl succinate, β-carotene, and L-lysine can prevent cancer metastases using as an adjuvant therapy.

Yunlong Cheng; Shu Lian; Shuhui LI; Yusheng LU; Jie Wang; Xiaoxiao Deng; Shengyi Zhai; Lee Jia

Return

Combination of Se-methylselenocysteine, D-α-tocopheryl succinate, β-carotene, and L-lysine can prevent cancer metastases using as an adjuvant therapy.

Author: Yunlong CHENG ¹ ; Shu LIAN ¹ ; Shuhui LI ² ; Yusheng LU ¹ ; Jie WANG ² ; Xiaoxiao DENG ² ; Shengyi ZHAI ² ; Lee JIA ³
Author Information

1. Fujian- Taiwan-Hongkong-Macao Science and Technology Cooperation Base of Intelligent Pharmaceutics, College of Materials and Chemical Engineering, Minjiang University, Fuzhou 350108, China.
2. Cancer Metastasis Alert and Prevention Center, Fujian Provincial Key Laboratory of Cancer Metastasis Chemoprevention, College of Chemistry, Fuzhou University, Fuzhou 350002, China.
3. Fujian- Taiwan-Hongkong-Macao Science and Technology Cooperation Base of Intelligent Pharmaceutics, College of Materials and Chemical Engineering, Minjiang University, Fuzhou 350108, China. cmapcjia1234@163.com.
Publication Type:Journal Article
Keywords: Cancer metastases; Cancer prevention; Combination of drugs; Nutrition; Selenium (Se)
MeSH: Mice; Animals; beta Carotene; Lysine/pharmacology*; Antioxidants/pharmacology*; Quality of Life; Paclitaxel/pharmacology*; Apoptosis; alpha-Tocopherol; Succinates/pharmacology*; Cell Line, Tumor; Cell Proliferation; Neoplasms
From: Journal of Zhejiang University. Science. B 2022;23(11):943-956
CountryChina
Language:English
Abstract: OBJECTIVES:Primary tumor treatment through surgical resection and adjuvant therapy has been extensively studied, but there is a lack of effective strategies and drugs for the treatment of tumor metastases. Here, we describe a functional product based on a combination of compounds, which can be used as an adjuvant therapy and has well-known mechanisms for inhibiting cancer metastases, improving anti-cancer treatment, and enhancing immunity and antioxidant capacity. Our designed combination, named MVBL, consists of four inexpensive compounds: L-selenium-methylselenocysteine (MSC), D-‍α‍-tocopheryl succinic acid (VES), β‍-carotene (β‍-Ca), and L-lysine (Lys).
METHODS:The effects of MVBL on cell viability, cell cycle, cell apoptosis, cell migration, cell invasion, reactive oxygen species (ROS), and paclitaxel (PTX)-combined treatment were studied in vitro. The inhibition of tumor metastasis, antioxidation, and immune enhancement capacity of MVBL were determined in vivo.
RESULTS:MVBL exhibited higher toxicity to tumor cells than to normal cells. It did not significantly affect the cell cycle of cancer cells, but increased their apoptosis. Wound healing, adhesion, and transwell assays showed that MVBL significantly inhibited tumor cell migration, adhesion, and invasion. MVBL sensitized MDA-MB-231 breast cancer cells to PTX, indicating that it can be used as an adjuvant to enhance the therapeutic effect of chemotherapy drugs. In mice, experimental data showed that MVBL inhibited tumor metastasis, prolonged their survival time, and enhanced their antioxidant capacity and immune function.
CONCLUSIONS:This study revealed the roles of MVBL in improving immunity and antioxidation, preventing tumor growth, and inhibiting metastasis in vitro and in vivo. MVBL may be used as an adjuvant drug in cancer therapy for improving the survival and quality of life of cancer patients.